Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FER | P16591 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797319 | 0.85 | LMNA (0.50) | LMNASLC34A1TP53GSK3BKCNA5 | |
| SCHEMBL16797383 | 0.78 | TP53 (0.44) | LMNAEGLN2SLC34A1TP53MARK3 | |
| SCHEMBL16797390 | 0.76 | ALDH1A1 (0.42) | LMNATP53MARK3ALDH1A1CYP2A6 | |
| SCHEMBL5846799 | 0.73 | ALDH1A1 (0.52) | LMNAEGLN2TP53KCNA5KDM4E | |
| SCHEMBL13312272 | 0.71 | CHUK (0.45) | LMNAGSK3BKDM4EALDH1A1 | |
| SCHEMBL959690 | 0.69 | EGLN2 (0.55) | LMNAEGLN2KDM4EALDH1A1 | |
| SCHEMBL16797303 | 0.69 | EGLN2 (0.51) | EGLN2 | |
| SCHEMBL6176222 | 0.67 | MAPK14 (0.61) | GSK3BMAPK14 | |
| SCHEMBL1721390 | 0.66 | SCN9A (0.54) | LMNAEGLN2KDRALDH1A1 | |
| SCHEMBL5150566 | 0.66 | ALDH1A1 (0.39) | LMNAEGLN2CDK2KDM4ETRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-02-21 | — | — | US | disclosed |
| EP-3189038-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-3080100-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2016037005-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2015089192-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | LMNA 2879/4885EGLN2 252/4885SLC34A1 4352/4885 |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | LMNA 2879/4885EGLN2 252/4885SLC34A1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.